Six-year outcomes of antivascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy

Hikichi, Taiichi

doi:10.1136/bjophthalmol-2017-310448

Cited by 24 publications

(16 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since long-term follow-up is difficult in ordinary clinical practice, the number of patients in each treatment group among various subtypes of PCV is relatively small, so that our results might need to be confirmed by further studies which include more subjects. Although we have examined the distribution of various treatment regimens among different subtypes of PCV, bias due to the small number of subjects seems to be unavoidable in such a study, which is similar to previous studies of long-term treatment for PCV [11][12][13][14][15][16]. Moreover, because of the retrospective nature of this study, long-term randomized clinical trials and prospective real-world studies are needed to investigate more effective treatment regimens for PCV according to imaging features.…”

Section: Discussionsupporting

confidence: 64%

“…An extensive study of the LAPTOP study reported a mean injection number of 14.8 for ranibizumab in the anti-VEGF monotherapy group over 5 years, in which the number of ranibizumab injection was 8.0 in 3 years after the LAPTOP study, while the number of aflibercept was 3.7 [14]. Another Japanese study reported a mean injection number of 18.2 for ranibizumab over 6 years [16]. Although conversive therapy of anti-VEGF agents might help reduce the injection number, other influential factors in real world should be taken into consideration.…”

Section: Discussionmentioning

confidence: 99%

“…Unlike clinical trials which enrolled subjects with restrict criteria prospectively, the efficacy of these treatment regimens needs to be confirmed in real world. Several studies have confirmed the efficacy of anti-VEGF therapies and PDT with additional anti-VEGF therapy for PCV over a long-term period [11][12][13][14][15][16]. However, long-term outcomes of initial combination therapy of PDT and anti-VEGF therapy in real world have not been reported.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Six-Year Real-World Outcomes of Antivascular Endothelial Growth Factor Monotherapy and Combination Therapy for Various Subtypes of Polypoidal Choroidal Vasculopathy

Yang

Yuan

Song

et al. 2019

Journal of Ophthalmology

View full text Add to dashboard Cite

The purpose of this study was to compare 6-year visual outcomes of antivascular endothelial growth factor (anti-VEGF) monotherapy and initial combination therapy of photodynamic therapy (PDT) and anti-VEGF therapy for polypoidal choroidal vasculopathy (PCV) in a Chinese population and to investigate imaging biomarkers associated with visual outcomes. Forty-eight treatment-naive PCV eyes of 46 patients were reviewed retrospectively, which underwent anti-VEGF monotherapy or initial combination therapy. PCV was classified into 2 subtypes. Mean best-corrected visual acuity (BCVA) using logarithm of minimal angle resolution and imaging morphological features was compared. No significant differences of mean BCVA changes were noticed between anti-VEGF monotherapy and combination therapy in either subtype 1 PCV or subtype 2 PCV during 6-year period (all P values >0.05). Compared with BCVA at baseline, the mean BCVA at 72 months deteriorated significantly in eyes with subtype 1 PCV (P<0.001), while the mean BCVA at 72 months remained stable in eyes with subtype 2 PCV (P=0.941). In subtype 2 PCV eyes with continuous retina pigment epithelium, the mean changes of BCVA in eyes treated with anti-VEGF monotherapy were better than those in eyes treated with combination therapy (P=0.020). Anti-VEGF monotherapy and combination therapy for various subtypes of PCV had comparable long-term visual outcomes in most cases in real world. Imaging biomarkers which correlate with visual outcomes and treatment response should be included in the classification of PCV and validated in real world.

show abstract

Section: Discussionsupporting

confidence: 64%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Six-Year Real-World Outcomes of Antivascular Endothelial Growth Factor Monotherapy and Combination Therapy for Various Subtypes of Polypoidal Choroidal Vasculopathy

Yang

Yuan

Song

et al. 2019

Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…In a previous 6-year study, the 3-year VA after PRN anti-VEGF therapy for patients with PCV was similar to the baseline VA. 17 Similarly, a 3-year study assessing a PRN regimen for PCV reported that the post-treatment improvement in VA persisted until a year after treatment, with VA deterioration. 18 These findings are consistent with those of the present study.…”

Section: Discussionmentioning

confidence: 98%

Five-year visual outcomes after anti-VEGF therapy with or without photodynamic therapy for polypoidal choroidal vasculopathy

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Various clinical trials have demonstrated the efficacy of anti-VEGF monotherapy in PCV, and currently, it has become one of the first-line treatments for PCV [6,7]. Both ranibizumab and aflibercept have been used for the treatment of PCV.…”

Section: Introductionmentioning

confidence: 99%

Comparison of the Efficacy of Three Loading Doses of Intravitreal Injection of Conbercept with Injection Combined with PDT for the Treatment of PCV

Zhao

2020

BioMed Research International

View full text Add to dashboard Cite

Purpose. To compare the efficacy between initial 3-monthly intravitreal conbercept monotherapy and combination intravitreal conbercept with photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV). Methods. This is a retrospective, comparative study which involved 65 PCV eyes of 65 patients. According to the therapeutic regimen, the PCV patients were divided into two groups: 32 eyes with naive PCV received a PDT after the first intravitreal injection of conbercept (IVC) followed by pro re nata (prn) retreatment (combination group), and 33 eyes with naïve PCV received 3-monthly IVC monotherapy followed by prn regimen (IVC monotherapy group). All patients completed at least 6 months of monthly follow-up. Results. At month 6, best-corrected visual acuity (BCVA) improved significantly (P<0.05) in both groups compared with that at baseline; the mean changes of BCVA between the IVC monotherapy group and combination group have no significant difference (−0.22±0.22 vs. −0.17±0.22 LogMAR, P=0.38). The central retinal thickness (CRT) decreased significantly in the two groups (P<0.05), with no difference between the two groups (P=0.24). The complete regression rate of polyps was 58.6% (17 out of 29 eyes) in the IVC monotherapy group and 80.65% (25 out of 31 eyes) in the combination group, respectively (P=0.09, χ-squared test). The combination group required significantly fewer injections than the IVC monotherapy group (3.09±0.89 vs. 3.67±0.74, P=0.006). Conclusion. Conbercept monotherapy significantly improved visual acuity and effectively regressed polyps during 6-month follow-up time in the treatment of PCV.

show abstract

Six-year outcomes of antivascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy

Abstract: The results emphasised the efficacy of anti-VEGF therapy for preserving vision and the limitations of anti-VEGF therapy in that continuous treatment is required over an extended follow-up period.

Cited by 24 publications

References 22 publications

Six-Year Real-World Outcomes of Antivascular Endothelial Growth Factor Monotherapy and Combination Therapy for Various Subtypes of Polypoidal Choroidal Vasculopathy

Six-Year Real-World Outcomes of Antivascular Endothelial Growth Factor Monotherapy and Combination Therapy for Various Subtypes of Polypoidal Choroidal Vasculopathy

Five-year visual outcomes after anti-VEGF therapy with or without photodynamic therapy for polypoidal choroidal vasculopathy

Comparison of the Efficacy of Three Loading Doses of Intravitreal Injection of Conbercept with Injection Combined with PDT for the Treatment of PCV

Contact Info

Product

Resources

About